Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Multiple Myeloma 202Leukemia, Lymphocytic, Chronic, B-Cell 54Recurrence 37Neoplasms, Plasma Cell 30Lymphoma, Mantle-Cell 30Lymphoma 30Lymphoma, Follicular 29Lymphoma, Large B-Cell, Diffuse 27Leukemia 23Leukemia, Myeloid, Acute 22Lymphoma, Non-Hodgkin 21Lymphoma, B-Cell, Marginal Zone 15Myelodysplastic Syndromes 13Hodgkin Disease 12Waldenstrom Macroglobulinemia 8Prostatic Neoplasms 8Lymphoma, T-Cell 8Smoldering Multiple Myeloma 7Immunoglobulin Light-chain Amyloidosis 7Neoplasms 6Melanoma 6Lymphoma, B-Cell 6Hematologic Diseases 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, Large-Cell, Anaplastic 5Leukemia, Myelomonocytic, Chronic 5Hematologic Neoplasms 5Amyloidosis 5Sezary Syndrome 4

Interventions

ruxolitinib 4Imatinib Mesylate 3ponatinib 2nilotinib 2Azacitidine 2spartalizumab 1sonidegib 1simtuzumab 1sabatolimab 1bosutinib 1Zoledronic Acid 1SCIO-469 1Lenalidomide 1Denosumab 1Decitabine 1Clofarabine 1CPI-0610 14-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Bone Marrow Diseases × Lenalidomide × Clear all
NCT01629082 2019-12-17

Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
4 enrolled
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Myelodysplastic Syndromes, Neutropenia, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡